Verenium extends marketing agreement with Alfa Laval for Purifine PLC enzyme

NewsGuard 100/100 Score

Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that it has renewed and extended its joint marketing agreement with Alfa Laval, a leading global provider of heat transfer, separation and fluid handling technologies, for Purifine® PLC.  In 2009 Verenium and Alfa Laval signed an agreement to jointly market enzymatic degumming of vegetable oils using Verenium's Purifine® PLC enzyme and Alfa Laval's engineering services and equipment.  

"Our collaboration with Alfa Laval has been successful on a number of levels," said Janet Roemer, Verenium's President and Chief Operating Officer.  "In addition to expanding Purifine® PLC's global market penetration, through working with Alfa Laval, we've also been able to enhance support of the Purifine® PLC enzymatic degumming process.  We look forward to building upon this successful collaboration as we work to secure continued growth for both businesses in the important global vegetable oil market."

Under the terms of the extended agreement, Verenium has granted Alfa Laval a non-exclusive license to jointly market, implement and support the Purifine® PLC process with their process engineering equipment and services to customers processing vegetable oils for edible or biodiesel purposes.  As part of this five year agreement, Alfa Laval will market Purifine® PLC to edible oils processing customers in agreed to territories.  In addition, Alfa Laval will continue its efforts on further developing the process for Purifine® PLC enzymatic degumming.

"Alfa Laval is pleased to be able to extend our partnership with Verenium which will allow us to continue to offer Purifine® PLC's novel enzyme technology to the vegetable oil processing industry," said Bent Sarup, General Manager for Alfa Laval's Vegetable Oil Technology Business. "Under the agreement we expect to further enhance the value created for our customers through continuous process improvements of this technology."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative COVID-19 test prototype uses bioluminescence for speedier results